Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study

Virgil A. Hatcher, Alvin E. Friedman-Kien, Edwin L. Marcus, Richard J. Klein

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.

Original languageEnglish
Pages (from-to)283-290
Number of pages8
JournalAntiviral Research
Issue number5
StatePublished - Oct 1982
Externally publishedYes


  • arabinosyladenine monophosphate
  • double-blind, placebo-controlled study
  • genital herpes


Dive into the research topics of 'Arabinosyladenine monophosphate in genital herpes: A double-blind, placebo-controlled study'. Together they form a unique fingerprint.

Cite this